Chest
Clinical Investigations: The PleuraFactors Predictive of Survival Among 337 Patients With Mesothelioma Treated Between 1984 and 1994 by the Cancer and Leukemia Group B
Section snippets
Study Design and Eligibility Criteria
Table 1 summarizes the seven phase II studies for the treatment of mesothelioma that have been conducted by the CALGB between 1984 and 1994. The eligibility criteria for all studies were almost identical and included the following requirements: histologically confirmed malignant mesothelioma with measurable or evaluable disease; Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 to 2 (<50% of waking hours in bed); expected survival >2 months; adequate nutrition; no prior
Patient Demographics
The profile of patients with mesothelioma treated on CALGB protocols is summarized in Table 2. Patients were generally male (83%), had good PS (ECOG PS=0 or 1; 81%), presented with chest pain (60%) or dyspnea (70%) after experiencing symptoms for <3 months (46%), had a history of asbestos exposure (62%) or smoking (72%), and had disease involving the pleura (94%). Age ranged from 23 to 83 years, with an average of 61.3 years.
The overall response rate and median survival for each treatment
Discussion
Numerous articles have examined the impact of various clinical factors on the prognosis or survival of patients diagnosed as having mesothelioma. Table 525, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41 lists 17 of these articles, along with the time period during which these patient cohorts were diagnosed and the number of patients included in that cohort. The article by Spirtas et al,31 which reported on the largest patient cohort of 1, 475 patients, was based on information
Acknowledgments
Brian Samuels, Chandra Belani, Lisa Weissman, David Harmon, Karen Antman, Joseph Aisner, David Sugarbaker, James Holland, Maurice Barcos, and numerous other individuals within the CALGB contributed in a major way to this 10- to 15-year effort.
References (41)
- et al.
Prognostic factors in diffuse malignant pleural mesothelioma: a study of 167 patients
Chest
(1988) Malignant mesothelioma: prognostic factors in a prospective study of 98 patients
Lung Cancer
(1992)- et al.
The role of extrapleural pneumonectomy in malignant pleural mesothelioma: a Lung Cancer Study Group trial
J Thorac Cardiovasc Surg
(1991) - et al.
Benign and malignant mesothelioma
Malignant mesothelioma
Diagnosis and treatment of pleural mesothelioma
Semin Surg Oncol
(1990)Pleural mesothelioma
Curr Opin Oncol
(1991)- et al.
Chemotherapy in malignant pleural mesothelioma: a review
J Clin Oncol
(1996) - et al.
Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B
J Clin Oncol
(1993) - et al.
Carboplatin in malignant mesothelioma: a phase II study of the Cancer and Leukemia Group B
Cancer Chemother Pharmacol
(1990)
Dihydro-5-azacytidine in malignant mesothelioma using serum hyaluronic acid as a tumor marker: a phase II trial of the CALGB [abstract 1248]
Proc Am Soc Clin Oncol
Trimetrexate in malignant mesothelioma: a Cancer and Leukemia Group B phase II study
J Clin Oncol
Dihydro-5-azacytidine (DHAC) and cisplatin (DDP) in malignant mesothelioma [abstract 1470]
Proc Am Soc Clin Oncol
Dihydro-5-azacytidine (DHAC) and cisplatin (DDP) in mesothelioma (CALGB 9031) [abstract 1371]
Proc Am Soc Clin Oncol
Edatrexate for malignant mesothelioma: a phase II study of the Cancer and Leukemia Group B (CALGB) [abstract 1087]
Proc Am Soc Clin Oncol
Edatrexate with oral leucovorin rescue for malignant mesothelioma: a phase II study of the Cancer and Leukemia Group B (CALGB 9131) [abstract 1068]
Proc Am Soc Clin Oncol
Paclitaxol (Taxol) for malignant mesothelioma (MM): a phase II study of the Cancer and Leukemia Group B (CALGB 9234) [abstract 1382]
Proc Am Soc Clin Oncol
Pleuropneu-monectomy in the management of diffuse malignant mesothelioma of the pleura
Thorax
A proposed new international TNM staging system for malignant pleural mesothelioma: from the International Mesothelioma Interest Group
Chest
Nonparametric estimation from incomplete observations
J Am Stat Assoc
Cited by (454)
Established and new treatment roadmaps for pleural mesothelioma: opinions of the Turkish Collaborative Group
2023, Current Problems in CancerPleural mesothelioma
2022, Medicine (Spain)Medical and Surgical Care of Patients With Mesothelioma and Their Relatives Carrying Germline BAP1 Mutations
2022, Journal of Thoracic OncologyMalignant and borderline mesothelial tumors of the pleura
2022, Practical Pulmonary Pathology: A Diagnostic Approach
Supported by CA33601 (Dr. Herndon), CA31946 (Dr. Green), CA04457 (Drs. Chahinian and Suzuki), and CA41287 (Dr. Vogelzang).